For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Subjects with advanced/metastatic Colorectal Cancer(CRC) who have failed or been intolerant to both irinotecan- and oxaliplatin- based regimens

Subjects with advanced/metastatic Squamous cell carcinoma of the head and neck (SCCHN) who are without options for curative treatment

Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

Men and women 18 and older

Women of childbearing potential (WOCBP) and men must use highly effective methods of contraception

Eastern Cooperative Oncology Group (ECOG) of 0 or 1

Subjects must have a life expectancy of at least 3 months

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer